Published in Leukemia on March 01, 1998
Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica (2011) 1.13
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood (2008) 1.11
Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci (2009) 0.94
Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study. Curr Ther Res Clin Exp (2006) 0.83
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol (2013) 0.83
Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. Neurol Sci (2008) 0.76
Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial. Iran Red Crescent Med J (2015) 0.75
Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature (1990) 6.71
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med (1990) 3.21
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med (1988) 2.44
Inhibition of protein synthesis in reticulocytes by antibiotics. I. Effects on polysomes. Biochim Biophys Acta (1966) 2.31
Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology (2001) 2.24
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
Inhibition of protein synthesis in reticulocytes by antibiotics. II. The site of action of cycloheximide, streptovitacin A and pactamycin. Biochim Biophys Acta (1966) 2.12
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03
High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes (2001) 2.02
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00
Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J (2002) 1.98
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology (1999) 1.88
Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.88
Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2008) 1.85
Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology (2010) 1.85
Paraplegia following coeliac plexus block. Pain (1993) 1.85
Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A (1996) 1.81
Model for antenatal diagnosis of beta-thalassaemia and other monogenic disorders by molecular analysis of linked DNA polymorphisms. Nature (1980) 1.79
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. AJNR Am J Neuroradiol (2001) 1.75
The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology (2006) 1.72
Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol (1994) 1.72
The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med (1993) 1.71
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology (2011) 1.68
A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2009) 1.64
Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology (2008) 1.63
Transperitoneal laparoscopic versus open adrenalectomy for benign hyperfunctioning adrenal tumors: a comparative study. J Urol (1995) 1.62
Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest (1993) 1.61
Safety of retroviral gene marking with a truncated NGF receptor. Nat Med (2003) 1.60
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain (2003) 1.60
Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol (2011) 1.58
Denaturing gradient gel electrophoresis analysis of the 16S rRNA gene V1 region to monitor dynamic changes in the bacterial population during fermentation of Italian sausages. Appl Environ Microbiol (2001) 1.57
Electrophysiological and MRI evaluation of neurological involvement in Behçet's disease. J Neurol Neurosurg Psychiatry (1989) 1.54
Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol (1999) 1.54
Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae. Int J Food Microbiol (2001) 1.52
In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain (2007) 1.48
The relationship between cervical secretions and the daily probabilities of pregnancy: effectiveness of the TwoDay Algorithm. Hum Reprod (2001) 1.47
Regulation of haemoglobin synthesis at the polysome level. J Mol Biol (1966) 1.47
Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol (1998) 1.44
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology (2010) 1.44
Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry (2000) 1.43
IFCN standards for digital recording of clinical EEG. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol (1998) 1.43
Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Mult Scler (2012) 1.42
The "mirror-neuron system" in MS: A 3 tesla fMRI study. Neurology (2007) 1.42
Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol (1999) 1.42
Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage (2002) 1.41
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
Neurodegeneration in the course of Langerhans cell histiocytosis. Neurol Sci (2011) 1.40
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology (2000) 1.39
Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment. Ital J Neurol Sci (1996) 1.39
A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology (1995) 1.38
Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. Ann Neurol (2001) 1.35
Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther (1998) 1.34
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol (2001) 1.29
Antibody responses to Four Corners hantavirus infections in the deer mouse (Peromyscus maniculatus): identification of an immunodominant region of the viral nucleocapsid protein. J Virol (1995) 1.28
Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology (2000) 1.28
Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol (1999) 1.28
Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia (2005) 1.28
Protection against malaria morbidity: near-fixation of the alpha-thalassemia gene in a Nepalese population. Am J Hum Genet (1991) 1.28
Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. Brain (1996) 1.27
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology (2010) 1.27
Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol (1999) 1.27
Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology (2010) 1.27
Late-onset cerebellar ataxia with hypogonadism and muscle coenzyme Q10 deficiency. Neurology (2004) 1.22
The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology (2010) 1.22
Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler (2007) 1.21
A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology (2011) 1.20
Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology (2001) 1.20
Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis. A comparison of techniques. Brain (1995) 1.20
The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology (2004) 1.20
IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Ther (2008) 1.18
A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care (1997) 1.17
In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain (2001) 1.17
Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am J Neuroradiol (2001) 1.16
Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant (2009) 1.15
Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology (1998) 1.15
A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging. Arch Neurol (2000) 1.14
Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler (2009) 1.13
Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol (2001) 1.13
Daily fecundability: first results from a new data base. Demogr Res (2000) 1.12
Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci (1994) 1.12
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci (2011) 1.11